Moclobemide and imipramine in chronic depression (dysthymia): An international double-blind, placebo-controlled trial

International Clinical Psychopharmacology

Volumn 12, Issue 4, 1997, Pages 183-193

  Versiani, M ^a   Amrein, R ^b   Stabl, M ^b   Magistris, ^c   Udabe, R Ucha ^d   Da Costa, Delcir A ^e   Nardi, A E ^a   Capponi, R ^f  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Interventional Cardiology Department   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e Hospital Mater Dei   (Brazil)

^f UNIVERSITY OF CHILE   (Chile)

Author keywords

Antidepressant; Chronic disease; Chronic minor depression; Depressive disorder; Double blind Double depression; Drug treatment; Dysthymia; Dysthymic disorder; Imipramine; Moclobemide; Monoamine oxidase inhibitor; Placebo; RIMA; TCA

Indexed keywords

IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; TREMOR; VERTIGO;

EID: 0030801915     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199707000-00001     Document Type: Article

References (33)

1. Akiskal HS, Bitar ALL, Puzantin VR, Rosenthal TL and Walker PW (1978) The nosological status of neurotic depression. Archives of General Psychiatry, 35, 756-766.
2. Akiskal HS, Rosenthal TL, Haykal RF, Lemmi H, Rosenthal RH and Scott-Straus A (1980) Characterological depressions: clinical and sleep EEG findings separating "sub-affective dysthymias" from "character spectrum disorders". Archives of General Psychiatry, 37, 777-783.
3. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition Revised (DSM-III-R). American Psychiatric Association, Washington.
4. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV). American Psychiatric Association, Washington.
5. Bakish D, Bradwejn J, Nair N, McClure J, Remick R and Bulger L (1992) A comparison of moclohemide, amitriptyline and placebo in depression: a Canadian multicenter study. Psychopharmacology, 106 (Suppl), 98-101.
6. Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B, Horn E, Browne M, Bourget D, Blanchard A et al. (1993) Ritanserin, imipramine and placebo in the treatment of dysthymic disorder. Journal of Clinical Psychopharmacology, 13, 409-414.
7. Boyer P and Lecrubier Y (1996) Atypical antipsychotic drugs in dysthymia: placebo-controlled studies of amisulpiride versus imipramine, versus amineptine. European Journal of Psychiatry, 11 (Suppl 3), 135-140.
8. Frances AJ (1980) The DSM-III personality disorders section: a commentary. American Journal of Psychiatry, 137, 1050-1054.
9. Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS and Barklage NE (1990) Clomipramine and obsessive-compulsive disorder: a placebo-controlled double-blind study of 32 patients. Journal of Clinical Psychiatry, 51, 292-297.
10. Harrison WM and Stewart JW (1993) Pharmacotherapy of dysthymia. Psychiatric Annals, 23, 638-648.
11. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, Burrows L, Poster M, Cantillon M and Winston A (1993) A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American Journal of Psychiatry; 150, 1169-1175.
12. Howland RH (1991) Pharmacotherapy of dysthymia: a review. Journal of Clinical Psychopharmacology, 11, 83-92.
13. Keller MB and Shapiro RW (1982) "Double depression": superimposition of acute depressive episodes on chronic depressive disorders. American Journal of Psychiatry, 139, 138-142.
14. Klein DF (1974) Endogenomorphic depression. A conceptual and terminological revision. Archives of General Psychiatry, 31, 447-454.
15. Kocsis JH, Frances AJ, Mann JJ, Mason BJ and Sweeney J (1985) Imipramine for the treatment of chronic depression. Psychopharmacology Bulletin, 21, 698-700.
16. Kocsis JH and Frances AJ (1987) A critical discussion of DSM-III dysthymic disorder. American Journal of Psychiatry, 144, 1534-1542.
17. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ and Sweeney J (1988) Imipramine treatment for chronic depression. Archives of General Psychiatry, 45, 253-257.
18. Lecrubier Y, Boyer P, Turjanski S and Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. Journal of Affective Disorders, 43, 95103.
19. Liebowitz MR, Gorman JM, Fyer AJ and Klein DF (1985) Social phobia: review of a neglected anxiety disorder. Archives of General Psychiatry, 42, 729-736.
20. Reyntjens A, Gelders YG, Hoppenbrouwers MJA, et al. (1986) Thymostenic effects of ritanserin (R 5667), a centrally acting serotonin S2 receptor blocker. Drug Developments Research, 8, 205-211.
21. Roth M, Mountjoy CQ, Amrein R and the International Collaborative Study Group (1996) Moclobemide in elderly patients with cognitive decline and depression. An international double-blind, placebo-controlled trial. British Journal of Psychiatry, 168, 149-157.
22. Schneider K (1967) Clinical Psychopathology [in German]. Georg Thieme Verlag, Stuttgart.
23. Sheehan DV, Ballenger J and Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
24. Spitzer R, Williams JB, Gibbon M (1987) Structured Clinical Interview for DSM-III-R (SCID I). Biometrics Research Department, New York Psychiatric Institute, New York.
25. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S and Leibowitz MR (1989) Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Archives of General Psychiatry, 46, 1080-1087.
26. Thase M-E, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum JF and Harrison W (1996) A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry, 53, 777-784.
27. The WPA Dysthymia Working Group (1995) Dysthymia in clinical practice. British Journal of Psychiatry, 166, 174-183.
28. Tyrer P, Murphy S, Kingdon D, Ferguson B, Kingdon D, Barczak P, Brothwell J, Darling C, Gregory S and Johnson SL (1988) The Nottingham Study of neurotic disorder: comparison of drug and psychological treatment. Lancet, 2, 235-240.
29. Vallejo J, Casto C, Catalan R and Salamero M (1987) Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorder. British Journal of Psychiatry, 151, 639-642.
30. Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin G, Marquez CA, Poleo MA, Rivero-Almanzor LE, Rossel L et al. (1989) A double-blind comparative trial of moclobemide vs imipramine and placebo in major depressive episodes. British Journal of Psychiatry, 155, (Suppl), 77-90.
31. Versiani M, Nardi AE, Figueira IL and Stabl M (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase -compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica, 360 (Suppl), 24-28.
32. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR and Amrein R (1992) Pharmacotherapy of social phobia: a controlled study with moclobemide, phenelzine and placebo. British Journal of Psychiatry, 161, 353-360.
33. World Health Organization (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). World Health Organization, Geneva.